CTD Clinical Follow-Up Still Needed For Breast Implants, FDA Maintains
This article was originally published in The Gray Sheet
Executive Summary
Breast implant patients should be monitored for symptoms of connective tissue disease annually for a minimum of 10 years post-implantation, FDA advises in final guidance to be issued Aug. 13.
You may also be interested in...
Breast Implant Patient Follow-Up Data Collection Crucial – FDA Guidance
Breast implant manufacturers should offer incentives in order to encourage patient cooperation with post-implant study data collection efforts, FDA advises in a final guidance document
Breast Implant Patient Follow-Up Data Collection Crucial – FDA Guidance
Breast implant manufacturers should offer incentives in order to encourage patient cooperation with post-implant study data collection efforts, FDA advises in a final guidance document
Silicone Breast Implant Return To U.S. Market Heralded By Modular PMA
Inamed likely will be first to the U.S. market with a silicone gel-filled breast implant in the wake of FDA's 1992 call for PMAs for the pre-amendments devices